BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230315T130000
DTEND;TZID=Europe/Brussels:20230315T190000
DTSTAMP:20260704T021649
CREATED:20221114T094047Z
LAST-MODIFIED:20230308T114450Z
UID:5505-1678885200-1678906800@www.europabio.org
SUMMARY:Biomanufacturing Platform - Policy Summit 2023
DESCRIPTION:EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation\, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for its understanding and recognition within policy. \n\n\n\nThe half day meeting will bring together Members and invited stakeholders from across the policy\, finance\, trade\, skills and regulatory spectrum surrounding biomanufacturing. \n\n\n\nDiscussion will address what biomanufacturing looks like across sectors and the roles played by SMEs\, large companies and expert services. The economic and skills footprint will be reviewed\, plus how it sits within Europe’s twin pillars of green and digital transition within the industrial strategy. Finally\, it can start to address how policy shapes and facilitates biomanufacture and Europe’s global position for such a transformative technology in action. \n\n\n\nFrom the first Summit\, a roadmap for biomanufacture can be developed for Europe and creation of a long term discussion platform for stakeholders through the Platform. \n\n\n\nAgenda \n\n\n\n14:00Opening plenary14:00Welcome and introduction to the Biomanufacturing Policy Summit– Claire Skentelbery\, Director General\, EuropaBio14:10Biomanufacturing in Europe’s industrial transition– Peter Dröll\, Director Prosperity\, European Commission\, DG Research and Innovation14:30Biomanufacturing as a global transition: US Executive Order for Biomanufacturing in focus– Hilary Stiss\, Director\, International Affairs\, Biotechnology Innovation Organization (BIO) 14:45Quo vadis European Biomanufacturing innovation in a competitive\, globalized world– Wojciech Nowak\, Global Senior Director\, Novartis15:00I am Biomanufacturing: examples in action        ● Resilience\, sustainability and competitiveness: Biomanufacturing in daily life: Ute Schick\, Senior Vice President Research\, Development and Innovation (RDI)\, Nutrition & Care (NC-RDI)\, Evonik Operations GmbH       ● Growing SMEs: Biomanufacturing in the next generation of industry: Jeroen Hofenk\, Founder and Chief Science Officer\, SwiftPharma       ● The national landscape: Belgium’s economic development through biomanufacturing: Tineke Van hooland\, Deputy Secretary General Bio.be       ● Advanced healthcare: The role of biomanufacturing in reaching rare diseases: Philippe Moyen\, VP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics15:30Break16:00Parallel Breakout discussionsBreakout 1 – Advanced healthcare: Role and growth in Europe● Role in Europe’s pandemic response. Scale and flexibility of manufacture – planning\, delivering\, investment● Patient access to advanced therapies (including rare diseases).● Competitiveness and economic contributor across EuropeBreakout 2 – Resilience\, competitiveness and sustainability:● Transition of industrial process for sustainability●  Building resilience of supply● Innovation for competitiveness17:10Closing plenaryClosing panel discussion: Europe’s ambition and pathway for biomanufacturingStakeholders from across the biomanufacturing landscape look at the future for Europe within biomanufacturing. The industrial goals it must achieve\, the pathway towards those goals and how it can make use of the skills\, infrastructure and policy/regulatory frameworks through which Europe develops.Moderator: Kristin Schreiber (Director DG GROW)Panelists: Peter Wehrheim (Head of Unit RTD.B2)\, Kristin Thompson (COO EUREKARE)\, Nessa Fennelly (Senior Executive IBEC)\, Nicolo Giacomuzzi-Moore (Executive Director CBE JU)\, Stefaan Fiers (Head of Corporate Communication\, Public Affairs and Patient Advocacy Takeda Belgium).18:00Networking reception19:00Close\n\n\n\n \n\n\n\nSpeakers \n\n\n\n\n\n\n\n\n\n\nHilary Stiss\n\n\n\nDirector\, International Affairs\, BIO Program Director\, ICBA \n\n\n\nAs a Director for International Affairs at the Biotechnology Innovation Organization (BIO)\, Hilary is responsible for managing the industry association’s program of international advocacy and outreach for multilateral organizations. Hilary also manages the association’s engagement in Europe\, the Middle East\, North Africa\, Turkey and South Africa regions. In this position\, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also acts as Program Director for the International Council on Biotechnology Associations (ICBA). \n\n\n\n\n\n\n\n\n\n\n\n\n\nClaire Skentelbery\n\n\n\nClaire holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions\, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network\, working across sectors\, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017\, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Ute Schick\n\n\n\nSenior Vice President Research\, Development and Innovation\, Evonik \n\n\n\nDr. Schick has a 20-year track record in global profit and loss responsibility at CEO and Senior Manager level within Food\, Health\, Cosmetic Industry and Material Science. Before her current role with Evonik\, she held roles as SVP of Supply Chain and Business Processes and VP of new Growth Business. Prior to working at Evonik she held roles at DuPont and DSM. \n\n\n\n\n\n\n\n\n\n\n\n\n\nWojciech Nowak\n\n\n\nGroup Senior Director\, Global Governmental and Public Affairs\, Novartis International\, Switzerland.(Functional responsibility for ca. 30 countries incl. Western & Eastern Europe\, Central Asia). \n\n\n\nMulticultural\, inclusive and reflective leader who lived in 6 countries on 3 continents.Robust understanding of the global healthcare policies and life-sciences business with more than 20 years of experience in policy creation related to healthcare systems\, EU integration and global pharmaceutical market. \n\n\n\nStarted his career at the Ministry of Health (Poland) counselling policy leaders on European integration and healthcare matters\, followed by assignments in the Ministry of Health and Solidarity of the Republic of France (Paris\, France) and Health Directorate of the European Commission (DG SANCO\, Luxembourg). \n\n\n\nAfter joining private sector has been serving in a number of senior leadership roles of growingresponsibility in healthcare companies(GlaxoSmithKline\, Abbott\, Novartis) on country\, regional and global levels (Poland\, Belgium\, Switzerland). \n\n\n\nEducated in Poland\, United States\, Nederlands\, Switzerland\, with the background in political sciences\, international relations (Warsaw’s University\, Poland; European Institute of Public Administration\, Maastricht\, Nederlands) and business administration (IMD Business School Lausanne\, Switzerland) he is an expert in healthcare systems\, global healthcare policies and international business. \n\n\n\nPassionate about delivering access and best healthcare outcomes to patients around the World. \n\n\n\n\n\n\n\n\n\n\n\n\n\nTineke Van Hooland\n\n\n\nDeputy Secretary general of bio.be/essenscia  \n\n\n\nTineke Van Hooland is Deputy Secretary general of bio.be/essenscia\, the Belgian federation of companies active in life sciences & biotechnologies. She’s also a board member at EuropaBio\, the European Association for Bioindustries\, from which she also chairs the NAC\, National Associations Council. Prior to this\, Tineke held several leadership positions in biopharmaceutical companies at the corporate level over the past years. She has in-depth expertise in Governmental Affairs\, Market Access\, Communication and Patient Advocacy. Tineke graduated with High Distinction as Industrial Pharmacist from Ghent University in 2003. \n\n\n\nTineke is also the founder and CEO of epic 10\, a boutique external affairs consultancy firm\, and a respected board member in various other organizations.  She is known for her dynamic and no-nonsense approach\, is a female leadership advocate and has authored a number of opinion pieces on sustainable health policy and empowering women. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Schreiber\n\n\n\nKristin Schreiber leads the Directorate Ecosystems I: Chemicals\, Food\, Retail\, Health in DG GROW\, the Directorate General for Internal Market\, Industry\, Entrepreneurship and SMEs. \n\n\n\nPrior to her current Director position\, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021). \n\n\n\nKristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla\, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition. \n\n\n\n\n\n\n\n\n\n\n\n\n\nStefaan Fiers\n\n\n\nCorporate Communications\, Public Affairs and Patient Advocacy Takeda \n\n\n\nStefaan is Head of Corporate Communications\, Public Affairs and Patient Advocacy at Takeda Belgium\, one of the largest pharmaceutical companies in Belgium. With his team\, he secures the healthcare policy analysis\, engages with external stakeholders and coordinates the company’s communication strategy. Additionally\, he oversees Takeda’s public affairs activities in 24 mid-sized European countries. \n\n\n\nBefore joining Takeda in June 2020\, he was Director of Communications and Public Policy at the Belgian pharma industry association pharma.be and held public policy positions in the pharma industry\, at Bristol-Myers Squibb Belgium/Luxembourg and at MSD Belgium.Next to his activities at Takeda\, Stefaan is an Associate Professor in Public Affairs and Comparative Politics at KU Leuven\, a Board member of PACE (Public Affairs Community Europe)\, and the author of several books and peer-reviewed articles. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPhilippe Moyen\n\n\n\nVP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics \n\n\n\nFollowing a university focus on therapeutic systems\, followed by formulation and industrial development\, Philippe has worked across the biotechnology spectrum including Baxter Healthcare\, Fresenius Kabi\, Stallergenes Greer\, and PTC Therapeutics where he has a strong focus on operations. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Thompson\n\n\n\nVP\, Chief Business Officer \n\n\n\nKristin Thompson is a former head of strategic partnerships in microbiomes at Bioaster. Before that\, Dr. Thompson was senior BD manager at Famar and BD manager of the French biotech company DaVolterra. She worked in research at French INSERM and the University of North Carolina\, Chapel Hill. She holds a Ph.D. in molecular biology from the University of Ulm\, Germany. \n\n\n\n\n\n\n\n\n\n\n\n\n\nNicoló Giacomuzzi-Moore\n\n\n\nExecutive Director ad interim\, Circular Bio-based Industries Joint Undertaking \n\n\n\nNicoló Giacomuzzi-Moore is CBE JU’s Executive Director ad interim and Head of the Administration and Finance Unit. He has been working in European affairs for more than 20 years\, focusing on research and innovation policy\, program implementation\, and enterprise support. \n\n\n\nBefore joining BBI JU (now CBE JU) in 2016\, he worked for the European Commission’s Research Executive Agency\, where he was responsible for financial and legal support in implementing European research projects. \n\n\n\nNicoló also worked for an Italian business association dealing with industrial policy and stakeholder management at the EU level. He holds a degree in economics and international trade. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Dröll\n\n\n\nDirector for Prosperity\, Directorate-General for Research and Innovation \n\n\n\nPeter Dröll has been working in the European Commission for more than 20 years with positions in the environment\, enlargement negotiations\, industry policy\, innovation\, and research. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik. \n\n\n\nSince 2010 he is at the Directorate-General of Research and Innovation where he was first responsible for Innovation and then for Industrial Technologies. Following the re-orientation of DG Research and Innovation towards sustainability\, his competencies have been enlarged to include industrial R&I agendas and business intelligence as well as knowledge valorization policies. \n\n\n\nBefore joining the European Commission in 1991\, Peter worked as a lawyer in a German law firm. Peter is a lawyer by training with a doctorate degree in German constitutional law and European law. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJeroen Hofenk\n\n\n\nFounder and Chief Science Officer\, SwiftPharma \n\n\n\nJeroen is a serial entrepreneur and scientist with a background in bioengineering and genetics. He has broad experience in CRISPR engineering and various expression platforms including microbial-\, animal cell-based\, and plants.  In the last 10 years of his career\, Jeroen has built a strong track record in plant-made-pharmaceutical manufacturing and the optimization thereof. He obtained 3 patent grants and holds 13 pending patents to his name.” \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Wehrheim\n\n\n\nHead of the Unit for the “Bioeconomy and Food System” within the Directorate General for Research and Innovation of the European Commission in Brussels \n\n\n\nWhile working for Phil Hogan\, Commissioner for Agriculture and Rural Development\, he contributed to the EU Bioeconomy Strategy. From 2010 to 2018 he was Head of the Unit for Land Use and Climate Finance in DG Climate Action. Before 2004 Peter worked at the Universities of Bonn/DE\, Maryland/US (with a Heisenberg scholarship from the German Research Foundation)\, and Kiel/DE. He received his doctoral degree in agricultural economics from the University of Giessen\, Germany \n\n\n\n\n\n\nAbout the EuropaBio Biomanufacturing Platform \n\n\n\nThe Platform has the mission to represent biomanufacturing at the highest policy levels in Europe\, to ensure that it is visible and recognised within the industrial strategy and Europe’s green and digital transitions. \n\n\n\nEuropaBio’s Biomanufacturing Platform will address the policy and wider frameworks through which biomanufacturing is delivered.  Together with members and stakeholders\, it will address how economic growth\, employment and resilience are achieved through policy\, legal frameworks and regulation at EU and national levels. \n\n\n\nThe Summit will be open to EuropaBio Members and invited stakeholders. Please contact c.skentelbery@europabio.org for further information.
URL:https://www.europabio.org/event/biomanufacturing-platform-policy-summit-2023/
LOCATION:BIP Meeting Center – House of the Capital Region\, rue Royale 2-4\, Brussels\, 1000\, Belgium
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/SM1-Quotes-Key-Messages-600-×-200px.png
END:VEVENT
END:VCALENDAR